Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics

被引:2
作者
Feng, Wei [1 ]
Chen, Xi [2 ]
Guan, Shao-xing [1 ]
Ruan, Hong-lian [3 ]
Huang, Yan [2 ]
Zhang, Hui-zhen [1 ]
Yang, Yun-peng [2 ]
Fang, Wen-feng [2 ]
Zhao, Hong-yun [2 ]
Zhuang, Wei [1 ]
Xin, Shuang [2 ]
Chen, You-hao [1 ]
Wang, Fei [4 ]
Gao, Yue [1 ]
Huang, Min [1 ]
Wang, Xue-ding [1 ]
Zhang, Li [2 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Inst Clin Pharmacol, Guangzhou 510006, Peoples R China
[2] Sun Yat Sen Univ, Dept Med Oncol, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Peoples R China
[3] Guangzhou Med Univ, Sch Publ Hlth, Guangzhou 510000, Peoples R China
[4] Guangzhou Univ Chinese Med, Ersha Dept Pharm, Affiliated Hosp 2, Guangzhou 510120, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
gefitinib; NSCLC; EGFR mutations; pharmacokinetics; metabolomics; CELL LUNG-CANCER; RECEPTOR TYROSINE KINASE; BRAIN METASTASES; OPEN-LABEL; PEMBROLIZUMAB; INHIBITOR;
D O I
10.1038/s41401-021-00791-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Gefitinib has been available in the market for 20 years, but its pharmacokinetic mechanism of response is little known. In this study, we examined the pharmacokinetic and metabolomic profiles in non-small cell lung cancer (NSCLC) patients with sensitive EGFR mutations. A total of 216 advanced NSCLC patients were enrolled, and administered gefitinib at the standard dosage of 250 mg/day, which was established in heterogeneous subjects with non-sensitive mutations. We identified and quantified three main metabolites (named as M1, M2 and M3) in the plasma of patients, the correlations between the concentration of gefitinib/metabolites and efficacy were analyzed. In exploratory and validation set, gefitinib concentration was not correlated with clinical effects. Considering the result that the therapeutic effects of 250 mg/2-day was better than that of 250 mg/day in a multiple center clinical trial, the standard dose might be higher than that for maximal efficacy according to the hypothetical dose-response curve. Among the three metabolites, the IC50 of M2 in HCC827 and PC9 cell lines was significantly lower, and Conc.(brain)/Conc.(plasma) of M2 in mice was significantly higher than those of gefitinib, suggesting its higher potential to penetrate blood-brain barrier and might be more effective in the treatment of brain metastatic tumor than gefitinib. Consistently and attractively, higher M2 plasma concentration was found to be correlated with better clinical outcome in patients with brain metastases (the median PFS of C-M2 < 12 ng/mL and C-M2 >= 12 ng/mL were 17.0 and 27.1 months, respectively, P = 0.038). The plasma concentration of M2 >= 12 ng/mL was a strong predictor of the PFS of NSCLC patients. In conclusion, for NSCLC patients with EGFR sensitive mutations, the standard dose is suspectable and could be decreased reasonably. M2 plays an important role in efficacy and may be more effective in the treatment of metastatic tumor than gefitinib.
引用
收藏
页码:1857 / 1864
页数:8
相关论文
共 23 条
[1]   Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer [J].
Bui, Nam ;
Woodward, Brian ;
Johnson, Anna ;
Husain, Hatim .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (05)
[2]   X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization [J].
Camp, RL ;
Dolled-Filhart, M ;
Rimm, DL .
CLINICAL CANCER RESEARCH, 2004, 10 (21) :7252-7259
[3]   FDA drug approval summary:: Gefitinib (ZD1839) (Iressa®) tablets [J].
Cohen, MH ;
Williams, GA ;
Sridhara, R ;
Chen, G ;
Pazdur, R .
ONCOLOGIST, 2003, 8 (04) :303-306
[4]   Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas [J].
Cortot, Alexis B. ;
Jaenne, Pasi A. .
EUROPEAN RESPIRATORY REVIEW, 2014, 23 (133) :356-366
[5]  
Frantz S., 2005, NAT REV DRUG DISCOV, V4, P95
[6]   Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? [J].
Frega, Stefano ;
Bonanno, Laura ;
Guarneri, Valentina ;
Conte, Pierfranco ;
Pasello, Giulia .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 128 :19-29
[7]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246
[8]   Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial [J].
Goldberg, Sarah B. ;
Schalper, Kurt A. ;
Gettinger, Scott N. ;
Mahajan, Amit ;
Herbst, Roy S. ;
Chiang, Anne C. ;
Lilenbaum, Rogerio ;
Wilson, Frederick H. ;
Omay, Sacit Bulent ;
Yu, James B. ;
Jilaveanu, Lucia ;
Thuy Tran ;
Pavlik, Kira ;
Rowen, Elin ;
Gerrish, Heather ;
Komlo, Annette ;
Gupta, Richa ;
Wyatt, Hailey ;
Ribeiro, Matthew ;
Kluger, Yuval ;
Zhou, Geyu ;
Wei, Wei ;
Chiang, Veronica L. ;
Kluger, Harriet M. .
LANCET ONCOLOGY, 2020, 21 (05) :655-663
[9]   Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial [J].
Goldberg, Sarah B. ;
Gettinger, Scott N. ;
Mahajan, Amit ;
Chiang, Anne C. ;
Herbst, Roy S. ;
Sznol, Mario ;
Tsiouris, Apostolos John ;
Cohen, Justine ;
Vortmeyer, Alexander ;
Jilaveanu, Lucia ;
Yu, James ;
Hegde, Upendra ;
Speaker, Stephanie ;
Madura, Matthew ;
Ralabate, Amanda ;
Rivera, Angel ;
Rowen, Elin ;
Gerrish, Heather ;
Yao, Xiaopan ;
Chiang, Veronica ;
Kluger, Harriet M. .
LANCET ONCOLOGY, 2016, 17 (07) :976-983
[10]   Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients [J].
Guan, Shaoxing ;
Chen, Xi ;
Wang, Fei ;
Xin, Shuang ;
Feng, Wei ;
Zhu, Xia ;
Liu, Shu ;
Zhuang, Wei ;
Zhou, Shan ;
Huang, Min ;
Wang, Xueding ;
Zhang, Li .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 172 :364-371